Neurolixis' Grant - VI Round

Neurolixis raised a round of funding on January 25, 2018. Investors include Parkinson's Disease Society of the United Kingdom.

Neurolixis is an early-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of human central nervous system diseases including Parkins…

Articles about Neurolixis' Grant - VI Round: